urlscan.io logo urlscan.io
SecurityTrails logo

endpts.com Open in urlscan Pro
13.227.219.61  Public Scan

Back to summary
Submitted URL: https://e.endpointsnews.com/t/t-l-vtutjtd-jhdldljikl-u/
Effective URL: https://endpts.com/gileads-kite-doubles-down-on-arcellxs-blood-cancer-cell-therapies-with-285m/
Submission: On November 17 via api from US — Scanned from DE

Form analysis 1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



November 15, 2023 07:15 AM EST
Deals
Cell/Gene Tx


GILEAD­'S KITE DOU­BLES DOWN ON AR­CEL­LX'S BLOOD CAN­CER CELL THER­A­PIES WITH
$285M


KYLE LAHUCIK

SENIOR REPORTER

Gilead’s cell ther­a­py unit Kite wants more of what it ini­tial­ly got from
Ar­cel­lx last De­cem­ber, buy­ing $200 mil­lion worth of eq­ui­ty in Ar­cel­lx
and dol­ing out $85 mil­lion in cash to ex­pand their part­ner­ship.

The deal ar­rives three months af­ter the FDA lift­ed a par­tial clin­i­cal hold
on the duo’s part­nered CART-ddBC­MA can­di­date in mul­ti­ple myelo­ma. The
re-upped pact will now ex­pand that scope to in­clude lym­phomas, the biotechs
said Wednes­day morn­ing, giv­ing in­vestors a lit­tle bit more lead time ahead
of the an­nu­al Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence than they did
with last year’s ini­tial an­nounce­ment.


UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER.

You’ll get access to free articles each month, plus you can customize what
newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER


TRENDING NOW


ASTEL­LAS DE­TAILS PO­TEN­TIAL REA­SON BE­HIND DEATHS IN RARE DIS­EASE GENE
THER­A­PY TRI­AL


Q&A: CAN ON­COLYT­IC VIRUS­ES MAKE A COME­BACK? EX­PERTS DIS­SECT CLIN­I­CAL
FAIL­URES AND OUT­LINE PATH FOR­WARD


DE­SIGN THER­A­PEU­TICS HINTS AT ‘STRATE­GIC RE­ALIGN­MENT,’ RE­PLACES CEO;
KARYOPHARM CO-FOUNDER LEADS AT­P'S NEREID


AS­TRAZENECA LANDS FDA AP­PROVAL FOR AKT IN­HIBITOR IN BIO­MARK­ER-DE­FINED
BREAST CAN­CER SUB­SET


LIL­LY IN­VESTS $2.5B IN NEW GER­MAN SITE TO BOOST TIRZEPATIDE SUP­PLY, $100M
FOR LO­CAL BIOTECHS

sponsored


CLIN­I­CAL STUD­IES IN JAPAN TO­DAY: AN­OTH­ER LOOK AT THE WORLD’S
SEC­OND-LARGEST PRE­SCRIP­TION DRUG MAR­KET IN A ...

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Coming soon


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.